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It is shown that if the numerical values of the coefficients and exponents of the polyexponentiaI 
equation describing the whole blood (plasma or serum) concentration after administration of a 
drug by bolus intravenous injection, or during or after termination of a constant-rate intravenous 
infusion, are known, then many needed pharmacokinetic parameters may be obtained directly. 
Parameters readily calculated by simple arithmetic are as follows: plasma or serum clearance, 
Clp; volume of plasma compartment, Vp; volume of distribution at steady state, Vass; Va .. . .  or 
Vt3, extrapolated volume of distribution, Vdex,; half-life of elimination, t]/2; amount metabolized 
and/or excreted to time t, (A~); amount in the body at time t, Ab; amount in the plasma 
(reference) compartment at time t, Ap; and amount in other compartments at time t, Ao. 
Simulations have shown that the equations yieM the correct answers for an n-compartment 
mammillary model with central compartment elimination only, when rate constants, dose, and a 
value of Vp have been assigned. Since whole blood (plasma or serum) concentration-time data 
always lead to ambiguities as to which specific model is involved, the equations are most 
appropriate. 
KEY WORDS: direct calculation of pharmacokinetic parameters; use of fitted polyexponen- 
tial equations; volumes of distribution; plasma clearance. 
I N T R O D U C T I O N  
In  a l i n e a r  p h a r m a c o k i n e t i c  s y s t e m ,  p l a s m a  c o n c e n t r a t i o n s  f o l l o w i n g  
b o l u s  i n t r a v e n o u s  i n j e c t i o n ,  i.v. C~; , will  b e  d e s c r i b e d  b y  a p o l y e x p o n e n t i a l  
Supported in part by Public Health Service Grant 5P11 GM 15559. 
1College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of 
Michigan, Ann Arbor, Michigan 48109. 
2Address reprint requests to Dr. John G. Wagner, Upjohn Center for Clinical Pharmacology, 
University of Michigan Medical Center, Ann Arbor, Michigan 48109. 
443 
9 1976 Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 10011. No part of this publication 
may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, 
photocopying, microfilming, recording, or otherwise, without written permission of the publisher. 
444 Wagner 
equation as in equation 1. Expanded forms of equation 1, corresponding to 
one, two, and three exponential terms are shown as equations 2-4, respec- 
tively. 
i.v. C~ = E Cie -~'t (1) 
i.v. e - X  l t C~; = C, (2) 
i.v. e --Alt e --A2t c~; = c~ + c~ (3) 
C~ v = C1 e -*it + Ca e-~2t + C3 e-X3t (4) 
In equations 1-4, Ci (C1, Ce, C3) are the coefficients, Ai (AI, Az, A3) are 
the exponents, and t is time. 
The numerical values of the C~'s and Ai's of equation 1 obtained from a 
given set of data depend on (a) the specific linear pharmacokinetic model 
(including exactly how many exit rate constants there are and where they 
exit from the one or more compartments), (b) the numerical values of the 
rate constants (kq's and k,o 's), (c) the dose, D, of the drug, and (d) the volume 
of the plasma (reference) compartment, Vp. 
In another article (1), it is shown that one and sometimes two terms of 
the polyexponential equation describing the plasma concentration after 
either intravenous or oral administration can readily vanish a few minutes 
after administration. This fact, coupled with the more complicated, nonclas- 
sical linear models discussed in that article, indicates that most of the time we 
cannot even determine which class of model we are dealing with. Also, there 
is no a priori reason to assume that all subjects or patients in a panel should 
have the same model for a drug. 
When only whole blood (plasma or serum) concentration-time data 
and/or urinary excretion data are available, there is really no rigorous 
method to determine whether elimination occurs only from the central 
(reference) compartment or from one or more of the peripheral compart- 
ments or both. Thus when evaluating such data the pharmacokineticist is 
presented with a dilemma. We have really not confronted this problem 
adequately to date. It has become customary in pharmacokinetics to assume 
one specific model for a given drug administered to a panel of subjects or 
patients, then to "force this specific model" on all sets of data, and to derive 
various kinetic parameters. There are three two-compartment open models, 
all of which give an equation of the form of equation 3 after bolus 
intravenous injection, There are 21 three-compartment open models, all of 
which give an equation of the form of equation 4 after bolus intravenous 
injection. We do not have the methods available to determine from the C~'s 
and Ai's of equation 1 which class of models or which specific model applies 
to a given set of data in either of these situations. In fact, relative to the 
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disposition model, unless special sampling procedures are used to detect 
peripheral metabolism or excretion, we have no recourse but to assume that 
all elimination processes occur only from the central compartment. 
Three proposals are being made in this article. These are as follows: 
1. Assume (unless there is strong evidence to the contrary) that the 
general modet which applies is an n-compartment mammiUary 
model with elimination only from the central (reference) compart- 
ment as shown in Scheme I. The methods given for calculation of all 
pharmacokinetic parameters in this article apply to this general 
model. (See the discussion section for further details.) 
2. Obtain a nonlinear least-squares fit of each set of data to the general 
equation 1, but use the number of  terms required for each set. Don't 
"force" all data sets in a group to either a biexponential or a 
triexponential equation. Reevaluation of many sets of literature 
data has revealed that data from some members of a panel require 
only one exponential term, others require two exponential terms, 
and others require three exponential terms; such results will be 
reported in a subsequent article. 
3. Calculate values of the pharmacokinetic parameters, such as Vp, 
Vass, Vdarea, Vaext, Clp, and tl/2 (see next section) directly from the 
coefficients and exponents of the fitted polyexponential equation. It 
is best to express the dose in mg/kg if the concentration data are in 
No. 2 
No. 3 ~ ~  
" U - 5  ~ 
No. 1 
~ klo 
Scheme I. The n - c o m p a r t m e n t  open mammil lary  model  on which the equat ions are based. 
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/zg/ml, and in/zg/kg if the concentration data are in ng/ml, so that 
the volumes will have dimensions of liters/kg; such values usually 
have smaller coefficients of variation than values in liters obtained 
from the same data. 
THEORETICAL 
Symbolism 
A5 is the amount of drug in the "body" (i.e., all compartments) at time t. 
(As)~ is the amount of drug in the "body" (all compartments) at time t 
in the terminal log-linear phase (i.e., only C l e  -xlt is still 
contributing). 
A~ s is the amount of drug in the "body" (all compartments) at time t at 
steady state. 
A i s is the average amount of drug in the "body" (all compartments) at 
steady state. 
Ae is the amount of drug which has been eliminated (metabolized 
and/or excreted) from the "body" in time t. 
Ap is the amount of drug in the plasma (reference) compartment at time 
t. 
Ao = A 5 - A p  is the amount of drug in compartments other than the 
plasma or reference compartment at time t. 
AUC is the area under the plasma concentration-time curve (subscripts 
give limits). 
Bi (i = 1, 2 . . . .  , n) is the coefficient of the ith exponential term of the 
polyexponential equation describing the plasma concentration fol- 
lowing oral administration (i.e., analogous to equation 1 except that 
Bi replaces Ci). 
C~ (i = 1, 2 , . . . ,  n) is the coefficient of the ith exponential term of the 
polyexponential equation describing the plasma concentration fol- 
lowing bolus intravenous administration. 
Clp is the plasma clearance (dimension of volume/time). 
Cp is the plasma concentration (i.e., concentration in the reference 
compartment with volume Vp) at time t. C iv refers to bolus intraven- 
ous administration and CPl ~ refers to oral administration. 
~ s  is the plasma concentration at time t at steady state. 
Cp s is the average plasma concentration at steady state. 
D is the dose of drug administered. For a constant-rate infusion 
D = koT. Dp.o. refers to oral administration and Di.v. refers to bolus 
intravenous administration. 
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DE is the loading dose. 
DM is the maintenance dose. 
Eij is the exit rate constant for the ith compartment and equals the sum 
of all first-order rate constants whose arrowheads point away from 
the ith compartment. 
F is the bioavailability factor concerned with incomplete absorption of 
the dose. 
F* is the bioavailability factor concerned with the so-called first-pass 
effect. This is defined by equation 28 when F = 1. For a given model, 
F *  is a combination of rate constants and F *  _< 1. 
f is the fraction of the drug which is free in the whole body. 
kij is a first-order "microscopic rate constant" for transfer of drug from 
the ith to the j th  compartment. 
kio is a first-order "microscopic rate constant" for transfer of drug from 
the ith compartment to outside "the body" or elimination rate 
constant of the ith compartment. 
k0 is the constant intravenous infusion rate (dimensions of mass/time). 
Ai is the exponent multiplying t in the exponential terms. Usually each 
Ai will be an eigenvalue which is the absolute value of one of the roots 
when the determinant is set equal to zero; in this case, the A~ is a 
function of all or many of the k~j's and kio's of the model. In some 
cases, the A~ is equal to one of the kq's. Note that A1 is the smallest Ai 
(classically symbolized by fl), A 2 is the second smallest Ai, etc.; i.e., the 
order of Ai's with respect to magnitude is the same as that obtained 
by stripping the data. Note that A~ refers to bolus intravenous 
administration or constant infusion and A~ p~  refers to oral 
administration. 
Oi (i = 1 or 2) are infusion rates (see equations 31 and 32 and text 
nearby). 
S; (i = 1 . . . . .  5) are particular sums defined by equations 5-9. 
y =E. 
i=1 
o" is the fraction of the drug which is free (not protein bound) in plasma. 
ll/2 is the apparent elimination half-life of the drug. 
T is the duration of a constant-rate intravenous infusion (dimension of 
time). 
r is the uniform dosage interval (dimension of time). 
to is a lag time sometimes introduced into a polyexponential equation 
for C p'~ for oral administration (dimensions of time). 
ts~ ~ is the time of the maximum plasma concentration after oral dosing 
at steady state. 
V/3 o r  Vdare a is defined by equations 6 and 13. 
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Vuss is the volume of distribution at steady state (based on the model of 
Scheme I). 
Vas~C'v s is the amount of drug in the body at time t at steady state. 
Va~C~p ~ is the average amount of drug in the body at steady state. 
V, is the volume of the plasma (reference) compartment. 
X~ is the coefficient of the ith exponential term of the polyexponential 
equation giving the plasma concentration during constant-rate 
intravenous infusion. 
Y~ is the coefficient of the ith exponential term of the polyexponential 
equation giving the plasma concentration after a constant rate infu- 
sion has ceased. 
Equations 
Equations for Bolus Intravenous Injection 3 
The plasma concentration is described by equation 1. 
Let 
5 1 :  E C i 
& = E G / a i  
s3 = Y. c~/a 2 
S4 = E ~ii e 
l ~  i ~ 







Then the plasma clearance, Clp, is defined by equation 10. 
Clp = Di.v./S2 = Di.v./AUCo-~ (10) 
The volume of the plasma compartment, Vp, is given by equation 11. 
Vp = Di.v./S1 (11) 
The volume of distribution at steady state, Vas~, is given by equation 12. 
Vds s = Di.v.S3/(S2) 2 (12) 
Wd . . . .  or Vt~ is given by equation 13. 
Vdare a = Di .v . /h  1 S 2 :  D/A l(AUCo-.oo) (13) 
3See Appendix for some derivations. 
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The extrapolated volume of distribution, Vaext, is given by equation 14. 
vd  ex, = D~ C1 (14) 
The elimination half-life, tl/2, is given by equation 15. 
tl/2 = 0.693/~1 (15) 
The amount which has been metabolized and/or excreted to time t, Ae, is 
given by equation 16. 
Ae = Di.v S5/ S2 = D (AUCo-~t)/(AUC0-~o) (16) 
It should be emphasized that equation 16 is mathematically correct only 
when elimination occurs solely from the central compartment. The amount 
of drug in the body at time t, Ab, is given by equation 17 (1). 
Ab = Di.v.S4/S2 = (Wd)t " Cp = D(mUCt-~oo)/(mUCo-~oo) (17) 
The amount of drug in the plasma compartment at time t, A e, is given by 
equation 18. 
i.v. i.v. Ap= Di.v.C~ /S~= VpC~ (18) 
The amount of drug in other compartments than the plasma compart- 
ment at time t, Ao, is given by equation 19. 
Ao = Ab - A e (19) 
Equations 19, in effect, lumps n peripheral compartments into one 
peripheral compartment. 
The time-dependent volume of distribution, (Va)t, is given by equation 
20, originally derived by Niazi (2). 
(Va)t =Ab/Cp i . v .  - -  = D i . v . S 4 / C p  $2 - D ( A U f t - , o o ) / C p ( A U C o - ) o o )  (20) 
It should be noted that the order of magnitudes of the volumes is always 
Vdoxt> Vdaro.> Vdss> Vp 
I t  should also be noted that (Ab)t~ = Vaare. " Cp, since (Va)t  = Vd.r~. in 
the log-linear phase when all exponential terms, except e -~lt, essentially 
equal zero. 
Relationship Between Bolus Intravenous and Infusion Equations 
The relationships between the bolus intravenous and intravenous infu- 
sion equations are shown in Table I for expansions up to and including three 
exponential terms. During a constant-rate intravenous infusion (t ~ T) the 
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plasma concentration is described by equation 21, and after the infusion has 
ceased (t -~ T) the plasma concentration is described by equation 22. 
= E X/(1 - e  -*,t) =EA@T(1 - e  -a't) G 
f e  +~'T l /  
G = E  Y~e = L G  
By matching coefficients, we see that 





Y/= C,-{ e ' ~  (24) 
From equation 23 we see that C~ = &TX~, and from equation 24 we 
obtain equation 25. 
&TY~ (25) 
C / -  e+X,r - 1 
Thus, if "during infusion" data are fitted to the X~ form of equation 21 
and/or "postinfusion" data are fitted to the II/form of equation 22, one can 
readily obtain the coeff• C~, corresponding to bolus intravenous 
injection and then apply equations 5-20 to obtain the pharmacokinetic 
parameters. Corrections are needed with equation 25 even when infusions 
as short as 5 min are given and postinfusion data are evaluated. 
Bioavailability 
Equation 26 symbolizes the result obtained by fitting a set of C~ ~  t 
data obtained following oral administration, if the system is linear. 
where 
Cpp.O. ~ n -ap.~ v, n t  -X~P'~ ].., i J  i e ' = 2..,1J i e (26) 
B'~ = Bi  e +x r~176 (27)  
Equations 26 and 27 include a lag time, to, which may be a positive 
value or zero. The program CSTRIP(3) automatically determines whether a 
lag time is needed to describe a given set of oral data. If to = 0, then Bi = B;. 
It should be noted that B~ can replace C~ and A p~ can replace Ai in 
equations 5 and 6. The result would give the sums S p~ and S p'~ respec- 
tively. If the latter values are then used in equations 10 and 13, with 
substitution of D p . o .  for Di .... then Clp/FF* and Va . . . .  /FF*, respectively, are 
























































































































































































































































































































































literature to ignore F* completely and assume F = 1 for oral administration, 
then claim that the parameters estimated are Clp and Vd . . . . .  This technique 
just causes confusion. 
By definition, the product FF* is given by equation 28. 
oo ~ Bi /Ai  (28)  FF~< : Ui.v. IOcx ]C p'~ dt Di.v. , p.o. 
Op.o. I0 Cp v" dt - Op.o. • Ci/Ai 
Thus F* is given by equation 28 when there is complete absorption of the 
oral dose (F = 1). 
The value of F* for a g!ven model is obtained by substituting the 
appropriate expressions for C~ v and Cp ~ into equation 28, letting Di.v. = 
Dp.o. and F =  1, then performing the integrations and simplifying the 
resultant ratio, or by use of Laplace transforms to obtain expressions for the 
areas. 
When real data sets have been fitted by the method of least squares and 
the numerical values of Di.v., Dp .... B'i, Ai are known, they may be substituted 
into the right-hand side of equation 28 and the value of FF* calculated 
directly. 
Drugs Bound to Plasma Protein and Tissues 
If or is the fraction of the drug which is free (not protein bound) in 
plasma, f is the fraction of the total drug in the body which is free, (A :)F is the 
intrinsic apparent elimination rate constant referenced to free drug, A 1 is the 
apparent elimination rate constant obtained from Cp, t data, and the one- 
compartment open model with linear plasma protein binding and linear 
tissue binding applies, then 
/~'1 = f(/~ 1)F (29)  
Clp = Vdext" /~-1 = Vdext " 0"" (/~l)F (30)  
For this particular one-compartment open model, Va .... = Vaext and both 
depend on bo th f  and or. This will be explained in a future publication by the 
author. 
Safe and Rapid Attainment of Steady-State Plasma Concentrations 
Once A1 and Clp are known for a linear system and a particular subject 
(or average parameter values are used), then steady-state plasma levels may 
be safely and rapidly attained by the method of Wagner (4). The steps are as 
follows: 
1. Choose the desired steady-state plasma concentration, C~ s. 
2. Choose the time T for the duration of the initial constant-rate 
intravenous infusion at the rate QI (mass/time). 
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3. Calculate the final infusion rate 02 (mass/time) for t ~ T with 
equation 31. 
02 = Clp. Cp s (31) 
4. Calculate the initial infusion rate, 01, for t ~ T with equation 32. 
01 = O2/(1 -- e -xlT) (32) 
Then, at zero time initiate the infusion at the rate Q~. At time T, abruptly 
change the rate from 01 to 02. Steady state is reached in about an hour or 
less after the rate Q2 is started. The amount of drug in the body at steady 
state, A~ ~, is given by equation 33. 
A~ s= Vass" ~ s  (33) 
Equations for Steady State After Oral Administration (5) 
When steady-state equation corresponding to equation 26 is equation 
34 when equal doses are given at equal time intervals, z. In equation 34, t is 
the time after a dose given at steady state. 
~f  B'i e - J ' r ~  ) 
@~= L~l_e_Xro.t ~ (34) 
To find the time of the maximum steady-state plasma concentration, 
t max, one takes the derivative of equation 34 and sets it equal to zero, then 
solves the equation by use of logarithms if these are only one or two 
exponential terms, or, iteratively, if there are more than two exponential 
terms. This is indicated by equation 35. 
d ~  -.-/'~ p.o. " --i/:l' e -,u~.o. tN,,, 
at = y  ] - - ~  = 0  (35) 
Once ts~ ax is known, then it may be substituted for t in equation 34 to 
yield the maximum plasma concentration at steady state, C~ ax, indicated by 
equation 36. 
BI e - ~ ~  ,xaxi 
csmax = Y' [ 1-- e-~-----~~ 7 j (36) 
The minimum plasma concentration at steady state, C min, is obtained by 
substituting ~- for t in equation 34, with the result shown as equation 37. 
,~ B~ e -x~ .... 1 C~ mi~ y. 
1 - e  -'~'7 . . . .  j (37) [ 
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To attain steady state quickly on oral dosing, the ratio of the loading 
dose, DL, to the maintenance dose, Din, is given by equation 38 (5). 
DL _ So Cp ~ dt_ V B;IA/p.o./y. 
Dm - Jo Cp d t  - z. [ A p'~ j 
(38) 
Similar equations to 34-38 may be used for bolus intravenous injec- 
tions given at intervals of ~" hr, but Bi is replaced by Ci and A p.o. is replaced by 
Ai (i.e., one uses equation 1 in place of equation 26). When the intravenous 
route is used, then the average steady-state plasma concentration, C~ s, is 
given by equation 39 (6). 
C~p s = D m / ( C l p  . r )  (39) 
If one substitutes the maintenance dose, D,,, the clearance, Clp, and the 
dosage interval, r, into the right-hand side of equation 39 for oral a d m i n i s -  
tration, the quantity estimated is CpS/FF * (since drug reaching the circula- 
tion is F F * D m  and not Din). However, if one had estimated an apparent 
plasma clearance, C l p / F F * ,  from oral data and used it in place of Clp in 
equation 39, then C~would be estimated. There is much confusion in the 
literature about such calculations. 
There is also some confusion in the literature as to what "clearances" 
mean. Various "clearances" were calculated for diphenhydramine from 
plasma concentrations measured both during and after a constant-rate 
intravenous infusion and after oral administration of similar (but known) 
doses of the drug given as an aqueous solution and in capsule form (7). 
Results obtained may be summarized as shown in Table II. It is obvious that 
F and F* are confounded. We can obtain an estimate of F* only if we assume 
F~ = 1 for the solution given orally. 
EXPERIMENTAL 
Example of Obtaining Coefficients of Bolus Intravenous Equations from 
Postinfusion Data 
For the two-compartment open model with elimination only from the 
central compartment, let k12=3, k21 = 2, kel=0.1, Di.v.= 500,000, lip = 
5000, ko = 250,000, and T =  2. For these constants, we find A1 = 0.03952 
and A2 = 5.0605 (see Appendix). For bolus intravenous injection, 
Di.v. 














































































































































































































































































































































Substitution of the assigned values into equation 40 yields equation 41. 
Cp = 39.0459 e-~176 + 60.9545 e -5"0605t (41) 
Hence Cz = 39.0459 and C2 = 60.9454. 
For postinfusion, 
k o ( k 2 1 - A 1 ) ( 1  - e  +;~IT) ko (k21 -A2) (1 -e  +x2T) 
e -:'2t (42) 
Cp -- _ ~ 1 ( ~ 2 _  A1) Vp e-Xat'+ _~2(~.1_~2)Vp 
Substitution of the assigned values into equation 42 yields equation 43. 




I<'1=40.6303 and Y2 = 149,712.2288 
TA 1 Y1 (2)(0.03952)(40.6303) 
C1 -- e+XlT _ 1 e +(0"03952)(2) -- 1 -- 39.0459 (44) 
TAzY2 (2)(5.0605)(149,712.2288) _ 60.9542 (45) 
C2 = e+A2 T _  1 = e +(5'0605)(2) -- 1 
The C1 and C2 values obtained with equations 44 and 45, respectively, 
are the same as those in the intravenous equation 41 within round-off error. 
Examples Showing That Equation 12 Yields the Correct Value of Vdss 
Example i 
Example 1 is of a two-compartment  open model with elimination only 
from the central compartment.  
Let  the constants be the same as in the above example, hence equation 
41 holds. 
Substituting from equation 41 into equations 6, 7, and 12 gives equa- 
tion 46. 
39.0459 60.9545 ] / [ 3 9 . 0 4 5 9  60.9545.] 2 
5 0 6 0 5 . 1  
= 12,501 (46) 
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For this model, Vd~s is known to be given by equation 47. 
Va~ = (1 + kaz/k21) Vp = (1 + 3/2)5000 = 12,500 (47) 
The difference of 1 in 12,500 is due only to round-off error in the C~'s 
and hl's. 
Example 2 
Example 2 is of a three-compartment open model with elimination only 
from the central compartment shown in Scheme II. The dose is put into 




By writing the differential equations for Scheme I, converting to 
Laplace transforms, and setting the determinant, A, equal to zero, one 
obtains equations 48-51, 
A= 
(S-f 'E1) -k21 -k31 
-k12  (S+k21)  0 
-k13  0 (S+k31)  
= S3 + a 2 S 2 + a l S  +ao=O (48) 
where 
a2 = E l  + k21+ k31 
a l  = Elk21 + Elk31 + k21k31 - k12k21 - k13k31 




There are three negative roots (eigenvalues) of equations 48-51 and the 
absolute values of these roots are designated A1, ha, and A3. The relation- 
ships are 
a2=AI+A2+A3 (52) 
a I = A 1A2 +/~ 1A3 --~- )t 2/~ 3 (53) 
a0 = AIA2A3 (54) 
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The Laplace transform of the amount of drug in compartment 1 at t, al ,  
is given by equation 55. 
D -k21 -k21 
0 (S+k21) 0 
0 0 (S+k31) D(S+k21)(S+k31)  
al = A - ( S + A 1 ) ( S + A 2 ) ( S + A 3 )  (55) 
Letting C~ v" = A l / W p ,  and taking the antitransform of equation 55, 
gives 
C~;V. Di.v. [(k21-A1)(k31-A1) _xat (k21-A2)(k31-A3) e_X2, 
= Vp I_ ~ ~  e -~ (Al-h2)(h3-A2) 
(k2a-A3)(k31 -/~3) ] 
q- (Al -h3) (ha-h3)  e-X~t (56) 
For example, let k12 = 3, k21 = 2, k13 = 1, k31 = 0.5, klo = 0.1, Di.v. = 
500,000, and Vp = 5000. Then 
E 1 = 0 . 1 + 3 + 1 = 4 . 1  (57) 
a2 = 4.1 + 2 + 0 . 5  = 6.6 (58) 
aa = (4.1)(2) + (4.1)(0.5) + (2)(0.5)- (3)(2)- (1)(0.5) = 4.75 (59) 
ao = (4.1)(2)(0.5)-(3)(2)(0.5)-(1)(2)(0.5)= 0.10 (60) 
Substituting from equations 58-60 into equation 48 gives 
S 3 + 6.6S 2 + 4.75S + 0.10 = 0 (61) 
An electronic calculator cube root program gave the roots of equation 
61 as -0.021705074, -0.796904816, and -5.7813901. 
Hence A1 -- 0.021705074, h2 = 0.796904816, and A3 = 5.7813901. 
Substituting these values into equations 52-54 gave the appropriate 
values of a2 = 6.6, al  = 4.75, and a0 = 0.10. 
Substitution of the values of D, Vp, k21, k31, h 1, A2, and h 3 into equation 
56 and simplification gave the equation 62. 
--0.796904816t C~; = i v  21.1921225 e -~176176176 +9.2944971 e 
+69.5633803 e -5"78139015t (62) 
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Substituting from equation 62 into equations 6, 7, and 12 gave equation 
63. 
21.1921225 9.2444971 69.5633803 ] / 
Vdss = 500,000 (0.021705074)2 § (0.796904816)24- ~ ~ j /  
.21.1921225 ~ 9.2444971 4-69"5633803] 2 
0.021705074 0.796909816 ~ ' J  
= 22,500 (63) 
For the particular three-compartment open model shown in Scheme II 
it is known that Vass is given by equation 64. 
Wdss = (1 q- k12/k213r k13/k31) Vp = (1 --]- 3/2 + 1/0.5)5000 = 22,500 
(64) 
Hence the new equation yields the correct value of Va~s for the model 
shown in Scheme II. In general, for any of the three-compartment open 
models, where elimination may be from any compartment, Vdss is given by 
equation 65. 
~ ss ~ SSdt+SoA3dt _ A b  _SoA1 dt+SoA2 ~ s~ 
Vds~ C~p ~ j0ff Cp s dt (65) 
The value of Vds~ given by equation 12 will exactly coincide with the value 
given by equation 65 only when the particular three-compartment open 
model shown in Scheme II is involved. However, since we usually cannot 
determine from which compartments elimination occurs, this is part of the 
pharmacokineticist's dilemma. Hence unless there are good reasons for the 
contrary, the author suggests that Vd~s always be calculated by means of 
equation 12. 
D I S C U S S I O N  
As discussed earlier (1, 5), there are many alternative models, all of 
which yield a two- or three-term exponential equation as illustrated by 
equations 3 and 4. It is getting to be common practice to measure some 
pharmacological response as a function of time and occasionally to conclude 
that the response is related to the amount of drug in compartment 1, 
compartment 2, or compartment 3. An alternative recommendation is to fit 
the data to the required number of exponential terms, then to determine if 
the response is approximately related to Ab (from equation 17) or Ao (from 
equations 17-19). This will tell one whether the site of action is in "the 
plasma compartment" or "some other part of the theoretical body" accord- 
ing to pharmacokinetic theory. However, the use of equations 17-19 will in 
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effect lump all peripheral compartments into one compartment. Whether 
this is a better alternative requires further study. It is important to know 
which compartment may relate to specific responses for specific drugs so that 
appropriate predictions and explanations may be made. To carry out such a 
determination accurately requires that plasma concentrations and responses 
be measured more than once shortly after intravenous administration as well 
as at later times. This is so since Ab is a maximum at time of injection and 
falls off whenever Ao is zero at time zero, rises to a maximum at some later 
time, and then falls off. Hence the distinction is made readily with data 
collected shortly after intravenous administration. 
Another point concerns degrees of freedom and what should be 
reported. If a bolus intravenous dose is administered and the plasma 
concentrations are fitted to a three-term exponential equation (equation 4), 
then one can report only six items as indicated by equation 4, namely C1, C2, 
C3, A1, A2, and A3. 
Fitting the data to equation 4 is a model-independent process. How- 
ever, one must realize that A i values must be widely separated (i.e., greater 
than two- to fivefold) for one to accept the validity of any computer fit. A 
six-parameter equation probably requires 18 or more data points properly 
spaced throughout the Cp,t curve. Assuming relatively accurate measure- 
ment, such data may yield a reasonable estimate of the parameters if the 
r e su l t an t  Ai values are sufficiently separated as noted above. Otherwise, the 
computer-derived exponentials must be considered as only our tentative, 
probably inaccurate estimate of the appropriate equation. 
If the data set fits the above restrictions, one can apply the equations 
listed in this article. Most of the equations 5-20 are model independent. 
However, equations 16 and 19 are model dependent, as noted earlier when 
they were originally discussed. Hence for consistency from one author to 
another it is here proposed that all authors use the general model shown in 




The plasma half-life, hi2, may be defined as the time required for the 
plasma concentration to fall to one-half its value after absorption has ceased 
and pseudo-steady-state distribution has been attained. The latter, for 
practical purposes, means that the amount of drug in each peripheral 
compartment is falling off essentially at the same first-order rate as the 
amount of  drug in the central (reference) compartment. Hence tl/2 is the 
apparent elimination half-life. It is defined by equation 15, and, in the 
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symbolism section, A1 is defined as the smallest of the Ai values. If the "rules 
are obeyed" and terminal plasma concentrations are well fitted by the 
polyexponential equation, then this definition is satisfactory. It will be h 1 
which has the most influence of all the Ai values in determining C~ i~ (see 
equation 37) and Cp S (see equations 39 and 10). The problem of not having a 
sensitive enough assay to "see" the correct value of ,~ 1, and the errors which 
ensue, has been discussed by Wagner (7). If Cp, t data have been correctly 
computer-fitted to the general polynomial equation, this parameter, as with 
all other coefficients and exponentials, is really model independent, and 
does not rely on the general model shown in Scheme I. 
Half-lives estimated from the other eigenvalues or kij's, such as 
0.693/A2 and 0.693/A3, have frequently been termed "distribution half- 
lives." But there are problems with such interpretations. If eigenvalues are 
involved, then they are a function of all the rate constants in the system and 
not just the microscopic distribution rate constants. If the coefficients and 
exponents of the polyexponential equation which is the "best fit" of each set 
of data are reported by an author, there appears to be no need to report the 
corresponding half-lives, since they may be readily calculated from the hi 
values. The terminal tl/2 (calculated from A 1) is the lone exception, and the 
reason for this is that scientists are used to thinking in terms of an elimination 
half-life rather than in terms of an apparent first-order elimination rate 
constant. 
Vdext 
By the nature of its calculation (equation 14), Vaext is also model 
independent, and does not actually rely on the general model shown in 
Scheme I. However, one of the commonest errors made in the literature is to 
assume that after a bolus intravenous injection Clp = Vaext" A1. This is true 
only when Vaext = Vaarea, as is the case with some drugs such as warfarin. The 
requirements for such a situation have been discussed by Albert et al. (8). 
When Vaext is appreciably larger than Va ..... then Vd~xt is of no use 
pharmacokinetically. When Va~xt ~ Vaar~a, then Va~xt is useful, since the 
latter parameter is more readily estimated (requiring fewer plasma assays) 
than Vdare a- 
If each set of data from a panel of subjects or patients is fitted with the 
appropriate number of  exponential terms for each subject, then Vp is also truly 
model independent, and does not rely on the general model shown in 
Scheme I. However, if one fits a given set of data to a biexponential equation 
when the data really require a triexponential equation, then the value of Vp 
estimated from the two equations will be different. 
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•dss 
The Vass value calculated with equation 12 applies only to the general 
model shown in Scheme I. However, because of the dilemma of not knowing 
from which compartments there are exit rate constants to "outside the 
body," use of equation 12 will at least make all authors homogeneous in 
their approach. 
Wdarea 
Equation 13 is based on mass balance considerations and is truly model 
independent when viewed in that light. However, (Ab)t3 = Vaar~a" Cp in the 
terminal log-linear phase only for the general model shown in Scheme I. 
Clp 
Equation 10 is based on mass balance considerations and is model 
independent when viewed in that light. However, Clp is equivalent to "total 
body clearance" only for the general model shown in Scheme I. If there were 
an exit rate constant, k20, from compartment No. 2 of Scheme I, then total 
body clearance would be equal to V~kao+ V2k2o and not equal to Clp, as 
calculated with equation 10. Many equate CIp with "total body clearance" 
without specifying under which conditions they are equivalent. 
Ae, Ab, and Ao 
Expressions Ae, Ab, and Ao calculated with equations 16, 17, and 19 are 
dependent on the general model shown in Scheme I. 
Conclusion 
Most pharmacokinetic articles on specific drugs report some or all of the 
parameters discussed above. The advantage of the equations in this article is 
that all of them may be calculated directly from the coefficients and 
exponents of the polyexponential equation without deriving any micros- 
copic rate constants. 
APPENDIX 
Derivation tor Ab Alter Bolus Intravenous Dose 
Io' Ab = Di.v. - Clp Cp dt (66) 
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Now, 
I0' Io' Cpdt= E Cie-*" dt'=~, . ( 1 - e  -A'') (67) 
Substituting from equation 10 for Clp and for the integral from equa- 
tion 67 into equation 66 gives 
a b = D i v - r D i v  ~C--2(1-e-a,t)/~CJai] 
" "  L " "  a i  
=Di~rl-E~(1-e-A,')/E c,/a,] 
9 "k ai 
=Di.~.[ Y. Cu/a, - Y, -~ii + Y, -~i e-X"/~ Ci/ai] 
=Div E -2Ci / e-A'* Z cJa~ = Di v 9 $4/$2 (68) 
" "  a i  " "  
Derivation for Vd~ After Bolus Intravenous Injection 
o ( ~,/ f ~ -~  ,/ 
Ab = A b d  r = D Z J o  ai(l_e_a,~)e-A'td rZG/a i  
Omitting the sum sign temporarily, we find that 
io ~ ~ ~" J ~ e~"~ a i ( 1 - e  -x';) e dt = a/2( 1 - e-X'~) 0 
G -,,, [ 






a ~(1 z e-*'~)] 
C/ __ e_a,.] = 
- a~(l_e_A,~)- [1 C//A] 
o r,:,,.v~ ] /  Ab = Z G/a  ~ Z G/A, 
1_ 'T 
Cff =~ C~S dt=Io Cpdt_Y~ Ci/ai 
T q" '1" 
= oi.v.Y, c,/a 2 





= Di.v. " $3/($2) 2 (73) 
4 ~  Wagner 
Time-Dependent Volume of Distribution After Bolus Intravenous Dose (2) 
(Vd)t is obtained by making a ratio of the above expressions for A b and 
Cp with the result below. 
Ab (Vcl)t=--~pp=Di.v.~ie-X't/[ ~ Cie-X't][~, Ci/Ai]=Di.v. 9 $4/C; v'. S 2 (74) 
In the log-linear phase only A 1 remains and (Vd),~ is given by equation 
11. 
Example Showing Relationship Between Coefficients for Cp, t Equations 
During Constant-Rate Infusion and Mter Bolus Intravenous Injection 





kl 2 4' 1 
ko [ ]  
kel 1 
k21 
Scheme III. Bolus intravenous injection. Scheme IV. During infusion. 
After bolus intravenous injection, equation 40 applies, where 
~ 1 "t-/~2 = k12+kzl+ke~ 
~1/~2 "~- kalkel 
II we write equation 40 as equation 77, 
Cp = Ca e-X1' + C2 e-X2' 
then by matching coefficients, we find 
D(k21 -/~1) 
G =  v,,(,~-,~l) 
-D(k21-o~) 
c2-  
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that 
During a constant-rate intravenous infusion, equation 80 applies: 
+Alt\ ko(k21_A2)(l_e+X2 t) ko(kzl-A1)(1-e ) e-Xlt.+ --A2 t 
Cp -- __al(/~2__/~1) Vp __X2(~1__ ~2) V p e 
ko(k21-al) ( l_e- ,1 ,)_ ~ ko(kz1-a2) 
--/~ 1(/~2--/~ 1) Wp ,~2(/~ 1-,~2) Vp (1 - e  -.2') (80) 
We may write equation 80 as equation 81. 
Cp = Xl(1 - e-*") +X2(1 - e -~`) (81) 
By matching coefficients of equations 80 and 81, we find 
ko(k21-a1) 
Xl = (82) 
a 1(A2 -- A 1) Vp 
ko(k21 -A2) ko(k21 -h i )  
X 2 - 1 ~ 2 ( a l _ l ~ . 2 ) V p  -.-~. ~2(/~2 _ ~t 1) V p (83) 
From the bolus intravenous equation 40 for the same model, we can see 
Also, 
Di.v.(k21 --A1) 
C 1 = (84) 
( /~2- -a l )  Vp 
-Di.v.(k21-hi) c2- (85) 
(/~2 --/~ 1) Vp 
Oi.v. 
k0 = - -  (86) 
T 
Utilizing equations 82, 84, and 86, we obtain equations 87-89. 
&= (a2-, 0V  _ 1 
(87) 
C1 )tlT(A2-A1)Vp Di.v.(k21-A1) A1T 
X 1 = C 1 / , ~  1 T (88) 
C1 = A, TX1 (89) 
Utilizing equations 83, 85, and 86, we obtain equations 90-92. 
X2=[-Di.v.(k21-1~l)][-(A2-A1)gp] 1 (90) 
C2 I-A2T(Az-Aa)VpJLDiv(k21-A1)J A2T 
X2 = Ca/A2T (91) 
C 2 = A2TX2 (92) 
4 ~  Wa~er 
Hence we may write the infusion equations as shown in Table I and 
equation 21. 
Post-intravenous-infusion equation 93 applies to Scheme IV. 
ko(ka1-)t1)(1-e +xlT) k0(kal-)t2)(1 --e +azz) e -*2t 
Cp -M( ) t z - )q )  Vp e-*"-~ - ) td) t l - ) t2)  Vp 
k o ( k 2 1 - ) t l ) ( e  + x l T -  1) k 0 ( k e l - ) t a ) ( e  +xzT- 1) e_,~ , (93) - e - * ~ t  _~ 
)t l()t 2 - - ) t l )  Vp )t 2()t 1 - ) t 2 )  Vp 
We may write equation 93 as equation 94. 
Cp = Y1 e-air + Y2 e-X2' (94) 
By matching coefficients in equations 93 and 94, we find 
ko(k21--) t  1)(e +a~T-  1) 
Y1 = (95) )t 1()t2 -)t 1) Vp 
ko(k21 - ) t  2)(e +x2T-  1) ko(k21--)te)(e +x2t -  1) 
II2 = - (96) 
)t 2()tl -- )t2) Vp )t 2()t 2 - )t 1) Wp 
Utilizing equations 84, 86, and 95, we obtain equations 97-99. 
+A1T e+X,T Y___~l= Di.v.(k21-)tm)(e - 1) ()t2-)t 1) Vp - 1 (97) 
C1 )tlT()t2-)tl)Vp Di.v.(k21 - ) t  1) ) t i T  
f e  +alT 1) 
YI=CI{ ~ / (98) 
)t 1TYI  (99) 
C1 = e +AaT- 1 
Utilizing equations 83, 86, and 96, we obtain equations 100-102. 
+A2T V2 [-Di.v.(ke,-)t2)(e T^2 --1)][--()t2--)tl)Vp]_e+a~T--1 
G = L  A2T()tz-)tl)Vp J L ~  ~--~2)J )tzT 
(100) 
"e +~2T -- 1 } 
Yz:C2{  ~--~- . (101) 
AzTY2 
C2 = e+,2r_ 1 (102) 
Hence we may write the infusion equations as shown in Table I and 
equation 22. 
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